VISTA
An immune checkpoint on myeloid cells that works at the acidic pH inside tumours and is a suspected escape route after PD-1 therapy; antibodies are in early trials.
VISTA (VSIR, PD-1H) is expressed mainly on myeloid cells and naive T cells, binds PSGL-1 selectively at acidic pH (tumour microenvironment) and VSIG3, and suppresses T-cell activation. It is upregulated after anti-CTLA-4 in prostate cancer and after chemotherapy in some tumours, suggesting adaptive resistance. Anti-VISTA antibodies (CI-8993, SNS-101 which binds only at low pH, HMBD-002, KVA12123) are in phase 1/2; the first agent (JNJ-61610588) was halted for cytokine release. No efficacy has yet been shown.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · An immune checkpoint on myeloid cells that works at the acidic pH inside tumours and is a suspected escape route after PD-1 therapy; antibodies are in early trials.
- 1 · What it is
An immune checkpoint on myeloid cells that works at the acidic pH inside tumours and is a suspected escape route after PD-1 therapy; antibodies are in early trials.
- 2 · What goes wrong in cancer
B7-family Ig-superfamily member acting as both ligand and receptor; histidine-rich extracellular domain makes PSGL-1 binding pH-dependent; expressed at high density on neutrophils, monocytes and MDSCs.
- 3 · How drugs use it
No product in this corpus aims at VISTA yet. Checkpoint drugs are antibodies that cover one side of an immune ‘stand down’ handshake so T cells stay active.
Biology
B7-family Ig-superfamily member acting as both ligand and receptor; histidine-rich extracellular domain makes PSGL-1 binding pH-dependent; expressed at high density on neutrophils, monocytes and MDSCs.
- Myeloid infiltrates in prostate, pancreatic, lung, colorectal and ovarian cancers
- Mesothelioma (tumour-cell expression)
- AML blasts
Latest papers
topQuery for this target: (TITLE:"VISTA" OR ABSTRACT:"VISTA" OR TITLE:"VSIR" OR ABSTRACT:"VSIR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VISTA, not a curated reading list.
Pages like this
not linked directly; found by shared links- TargetCD73 / adenosine axis
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, Pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors, Prostate cancer and the tag gap-fill.
- ProductPenpulimab
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-1, Immune checkpoint inhibitors and the tag gap-fill.
- ProductRetifanlimab
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-1, Immune checkpoint inhibitors and the tag gap-fill.
- ProductCosibelimab
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, Immune checkpoint inhibitors and the tag gap-fill.
- TargetPRMT5 (MTAP-deleted cancers)
Shares Mesothelioma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag gap-fill.
- ProductPexidartinib
Shares Myeloid suppression: TAMs, MDSCs & don't-eat-me signals and the tag gap-fill.
- TargetCSF1R
Shares Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Pancreatic ductal adenocarcinoma and the tag gap-fill.
- TargetCXCR4
Shares Myeloid suppression: TAMs, MDSCs & don't-eat-me signals and the tag gap-fill.